Form D · Biotechnology

SYNAGEVA BIOPHARMA CORP.

Lexington, MA · CIK 0001017163

Offering snapshot reported Mar 30, 2011 · SEC filing

Reported sold
$12.5M
Offering amount: $25M
Investors reported
22
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 15, 2011
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 30, 2011Initial$12,500,000No comparison22SEC filing
Aug 2, 2010Amendment$44,999,973$11,907,682vs May 7, 200928SEC filing
May 7, 2009Amendment$33,092,291No comparisonNot reportedSEC filing
Apr 16, 2009Initial$30,163,581No comparisonNot reportedSEC filing
Feb 2, 2009PaperNot reportedNo comparisonNot reportedSEC filing
Oct 15, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Aug 3, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Debt
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-157597

Source: Form D, filed Mar 30, 2011. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Srini Akkaraju Director
Felix Baker Director
Stephen Biggar Director
Mark Goldberg Director
Lyle Hohnke Director
Thomas Malley Director
Sanj K. Patel Director, Executive
Robyn Samuels Director
James Tullis Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
128 Spring Street, Suite 520
Lexington, MA, 02421